TrueBinding is a clinical stage biotherapeutic company founded in 2016 creating new and exciting molecules for applications in neurodegenerative diseases (AD, PD, ALS), stroke, metabolic diseases, oncology and other disease areas with great unmet medical needs. 

Based on its proprietary Truebinding™ platform, TrueBinding has to date discovered over 6 novel drug targets and developed potentially game changing monoclonal antibody drugs.